Can a serum aldosterone level be drawn while the patient is on olmesartan?

Can You Draw an Aldosterone Level on Olmesartan?

Yes, you can draw a serum aldosterone level while a patient is on olmesartan, but the results must be interpreted with caution as olmesartan will artificially raise renin and may lower aldosterone levels, potentially causing false-negative screening results for primary aldosteronism.

Key Considerations for Testing on Olmesartan

Effect on Laboratory Values

Olmesartan, as an angiotensin II receptor blocker (ARB), directly interferes with the renin-angiotensin-aldosterone axis. According to the FDA label, olmesartan increases plasma renin activity (PRA) and angiotensin II levels while having minimal influence on aldosterone levels at therapeutic doses 1. However, research demonstrates that olmesartan significantly decreases both angiotensin II and aldosterone levels in hypertensive patients 2, 3, 4.

Guideline Recommendations

The 2025 Endocrine Society Clinical Practice Guideline provides clear direction on this issue:

• ARBs like olmesartan should ideally be withdrawn for 2 weeks before screening for primary aldosteronism 5
• These medications raise renin and lower aldosterone, which can lead to false-negative results
• If withdrawal is not safe or feasible, testing can proceed on medication, but interpretation must account for the drug's effects 5

When Testing Cannot Wait

If you must draw aldosterone while the patient remains on olmesartan:

• Recognize that the aldosterone-to-renin ratio (ARR) will be artificially suppressed
• The elevated renin from ARB blockade may mask autonomous aldosterone production
• If the initial screen is negative but pretest probability for PA remains moderate to high (resistant hypertension, hypokalemia), repeat testing after withdrawing olmesartan for 2 weeks if safe 5
• Consider using alternative antihypertensives during the washout period: calcium channel blockers, alpha-blockers, or hydralazine cause minimal interference 6

Clinical Algorithm

1. Assess safety of medication withdrawal: Can blood pressure and potassium be controlled on non-interfering agents?
2. If withdrawal is safe: Stop olmesartan for 2 weeks, use calcium channel blockers or alpha-blockers for blood pressure control, then test
3. If withdrawal is unsafe: Draw aldosterone and renin on olmesartan, but:
   • Interpret negative results with extreme caution
   • If clinical suspicion remains high despite negative results, repeat after medication adjustment
   • Correct any hypokalemia before testing, as this independently lowers aldosterone 5

Important Caveats

• Hypokalemia must be corrected before testing regardless of medication status, as low potassium suppresses aldosterone secretion and causes false-negative results 5
• The 2025 guidelines acknowledge that in patients with overt biochemical evidence (PRA <0.2 ng/mL/h and aldosterone >15 ng/dL by LC-MS/MS), confirmatory testing may not be required even on medications 5
• Research shows olmesartan reduces aldosterone more effectively than some other ARBs like azilsartan, suggesting its interference may be particularly significant 2

Bottom line: Drawing aldosterone on olmesartan is technically possible but diagnostically suboptimal. Withdraw the medication for 2 weeks if clinically feasible, or accept that on-medication results require careful interpretation and may necessitate repeat testing.